

## **Direct Oral Anticoagulant (DOAC) Reversal**

See also: GHNHSFT Guideline: [Oral Anticoagulants – management of bleeding](#)

### **Apixaban / Edoxaban\* / Rivaroxaban** – Life-threatening G.I. bleeds only ([NICE TA697](#))

**Andexanet alfa** (Ondexxya®) may only be prescribed for acute life-threatening G.I. bleeds that are not amenable to standard management including endoscopy, interventional radiology, and blood products. At the discretion of the Consultant Gastroenterologist doing the emergency endoscopy, it may be felt appropriate to administer DOAC reversal prior to the procedure.

Andexanet alfa may only be prescribed for acute life-threatening G.I. bleeds by a senior clinician following Consultant Gastroenterologist authorisation (with Haematologist advice as necessary).

**Andexanet alfa may NOT be used for non-G.I. bleeds**

Dose: (see [SPC](#) and [Medusa](#) for further details)

Low dose (5 x 200mg vials): Initial i.v. bolus 400mg at a rate of 30mg/min  
Continuous i.v. infusion 4mg/min for 2 hours

High dose (9 x 200mg vials): Initial i.v. bolus 800mg at a rate of 30mg/min  
Continuous i.v. infusion 8mg/min for 2 hours

DOAC to be reversed	DOAC last dose	Timing of last DOAC dose	
		< 8 hours ago or unknown	≥ 8 hours ago
Apixaban	≤5mg	Andexanet alfa x <b>5 vials</b>	Andexanet alfa x <b>5 vials</b>
	>5mg or unknown	Andexanet alfa x <b>9 vials</b>	
Edoxaban*	≤30mg	Andexanet alfa x <b>5 vials</b>	Andexanet alfa x <b>5 vials</b>
	>30mg or unknown	Andexanet alfa x <b>9 vials</b>	
Rivaroxaban	≤10mg	Andexanet alfa x <b>5 vials</b>	Andexanet alfa x <b>5 vials</b>
	>10mg or unknown	Andexanet alfa x <b>9 vials</b>	

To be administered using an infusion pump via an in-line 0.2 or 0.22 micron low-protein filter

List price:

- Low dose (5 vials) = £13,875
- High dose (9 vials) = £24,975

Andexanet alfa is stocked in the medication fridge in ED: **GRH ED Resus**

**CGH ED Central Nurses' Station Fridge**

\*Note: Andexanet alfa is not licensed to reverse edoxaban; however, GHNHSFT approves the off-label use of andexanet alfa for reversing edoxaban provided it is used in accordance with the recommendations made within NICE TA697 for apixaban and rivaroxaban. The ANNEXA-4 study showed that for patients taking edoxaban, andexanet alfa significantly decreased anti-factor Xa activity (median decrease 71.3%; 95% CI: 65.2–82.3%) and excellent or good haemostasis at 12 hours was observed in 78.6% (95% CI: 59.0–91.7%) of patients overall.

## **Dabigatran**

**Idarucizumab** (Praxbind®) may only be prescribed for acute life-threatening bleeds that are not amenable to standard management

Idarucizumab may only be prescribed by a senior clinician following Consultant Haematologist (or Gastroenterologist for G.I. bleeds) authorisation.

*Dose: (see [SPC](#) and [Medusa](#) for further details)*

5g (2 x 2.5g/50ml vials given consecutively via i.v. infusion each over a period of 5-10 minutes).

Administration of a second 5g dose of idarucizumab may be considered if life-threatening bleeding recurs, together with prolonged clotting times.

*List price:*

- 5g = £2,400

Idarucizumab is stocked in the medication fridge in ED: **GRH** ED Resus

**CGH** ED Central Nurses' Station Fridge